Understanding how the tumor environment affects lung cancer treatment resistance
The Role of the Tumor Microenvironment in Resistance to Oncogenic KRAS Inhibition in Lung Cancer
This study is looking at how the area around lung tumors affects the way they respond to treatments, especially for patients with a specific type of lung cancer that has a KRAS mutation, to help find better ways to overcome treatment resistance.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11003365 on NIH RePORTER |
What this research studies
This research investigates the role of the tumor microenvironment in lung cancer, particularly focusing on how it contributes to resistance against treatments targeting the KRAS oncogene. By utilizing advanced techniques like single-cell RNA sequencing, the study aims to analyze changes in the tumor environment during treatment and recurrence. The goal is to identify mechanisms of resistance that could inform future therapies, especially for patients with non-small cell lung cancer who have specific KRAS mutations. This research could lead to improved treatment strategies that enhance the effectiveness of existing therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with non-small cell lung cancer harboring KRAS mutations, especially those who have not smoked.
Not a fit: Patients with lung cancer that does not involve KRAS mutations or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for lung cancer patients, particularly those with KRAS mutations.
How similar studies have performed: Previous research has shown promising results in targeting KRAS mutations, indicating that this approach has potential for success.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Galban, Stefanie — University of Michigan at Ann Arbor
- Study coordinator: Galban, Stefanie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.